The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats. We examined the effects of daily cyclophosphamide administration on the development and extent of tubulointerstitial nephritis produced in rats injected with tubular basement membranes in adjuvant. 15 mglkglday of cyclophophamide completely blocked the development of interstitial lesions, while 2 mg/kg/day enhanced the degree of interstitial injury.
© 1986 by the International Society of Nephrology because of its alkylating action on DNA in rapidly proliferating cells [8] [9] [10] . The treatment of interstitial nephritis in humans, on occasion, has also included the use of cyclophosphamide [11] . The experimental or clinical efficacy of this drug, however, has not been evaluated in the setting of primary interstitial renal disease.
Methods
Animals. Female Brown Norway rats, weighing 100 to 120 grams, were obtained from the Charles River Breeding Laboratories (Wilmington, Massachusetts, USA). They were maintained by the Department of Laboratory and Animal Medicine, University of Pennsylvania, School of Medicine.
Preparation of the antigen. Rabbit renal tubular basement membrane antigen (RTA) and liver basement membrane antigen were isolated by a differential seiving technique [1] . Highly enriched basement membrane fragments were sonicated, lyophilized, and stored at -70°C. Soluble renal tubular antigen (SRTA) and soluble liver antigen (SLA) were made from these lyophilized membranes using collagenase digestion [1, 2] . PPD was obtained from Connaught Laboratories (Ontario, Canada).
Induction of disease. Groups of rats were immunized with 2 mg of RTA in complete Freund' s adjuvant (CFA) by footpad or subcutaneous injection [1] . Control animals received CFA alone.
Cyclophosphamide (CTX) administration. Cyclophosphamide (Cytoxan, Mead-Johnson, Evansville, Indiana, USA) was freshly prepared in distilled water (0.5-5.0 mg/mi). The drug was administered intraperitoneally within one hour of preparation (either 2 or 15 mg/kg/day). Three drug protocols were used for analysis. In the first study cyclophosphamide was administered from days ito 21 after immunization; in the second study it was given from days 12 to 33, and; in the third study from days 21 to 42. All animals were sacrificed either on days 21, 33, or 42, respectively. Control animals received equal volumes of distilled water in an identical fashion. Assessment of renal disease. Kidney tissue was prepared for immunofluorescent and light microscopy by standard methods for this laboratory [121. Direct immunofluorescence of tubular staining by aTBM-Ab was graded from 0 to 4 and expressed as a mean SEM for each group [1, 12] . Kidneys fixed in 10% Reported as cells/cubic mm. * P < 0.003 compared to RTAICFA group (A).
formalin were stained with hematoxylin and eosin. Coded multiple, complete longitudinal sections were examined by a blinded observer and graded (mean SEM) according to the extent of involved cortex on a scale of 0 to 4 [121: 0 = normal; 0.5 = small focal areas of cellular infiltration, 1 = cellular infiltration and tubular damage involving less than 10% of the cortex; 2 = involvement up to 25% of the cortex; 3 = involvement up to 50 to 75% of the cortex, and; 4 = extensive damage involving more than 75% of the cortex. The presence of aTBM-Ab in serum was determined by solid-phase radioimmunoassay [11. Pooled serum creatinines were measured using the modified methods of Jaffe [13] .
Induction and elicitation of a delayed-type hypersensitivity (DTH) A) aTBM-Ab titers from rats reported in Table 1 cyclophosphamide at 2 mg/kg/day (Group D), or 15 mg/kg on day 1, and 2 mg/kg/day thereafter (Group C), demonstrated substantial amounts of kidney-bound rTBM-Ab, and only slightly reduced aTBM-Ab titers by radioimmunoassay (see Figure 1A ) compared to Group A. Both Groups C and D, however, developed more histologic disease (Group D just missmg statistical significance; P < 0.06). The changes in serum creatinines in both of these latter groups tended to be higher, paralleling the histologic evidence of more severe disease. The histologic lesions produced in these Brown Norway rats were similar to those previously reported [15, 16] . The disease was confined to the renal cortex, and began as focal cellular infiltrates which gradually became diffuse, producing tubular diitation and disruption of the tubular architecture. The glomeruli were not involved, and remained normal in appearance until they were trapped within an enlarging interstitial inifitrate (Fig. 2) . Effects of daily cyclophosphamide administration beginning early (12 days) after immunization to produce disease. Four groups were studied to evaluate the effects of cyclophosphamide on early, established interstitial disease. Non-drug treated rats immunized with RTA and CFA were sacrificed on days 12 and 33. Another group received 15 mg/kg of cyclophosphamide from days 12 to 33, and a fourth group immunized with CFA served as a negative control. By 12 days after immunization with RTA/CFA, the time-control rats had already developed early but substantial interstitial lesions (Table 2) . Untreated, the degree of interstitial damage progressed by day 33 and was associated with a persistently elevated serum creatinine. The group receiving 15 mg/kg/day of cyclophosphamide beginning on day 12 did not progress and, in fact, had a slightly reduced mean histologic score when compared to the rats sacrificed on day 12. Cyclophosphamide treatment also had a protective effect on the serum creatinine. The cyclophosphamide treatment, however, did not alter the amount of aTBM-Ab bound along the tubular basement membrane, but did affect the overall level of serum aTBM-Ab by day 33 (Fig. lB) .
Since the cyclophosphamide treatment beginning on day 12 had a pronounced effect on bone marrow production of WBC's (Table 2) , we were interested in determining its impact on the effector cell-mediated immune response to tubular antigen. We have previously demonstrated that the delayed-type hypersensitivity (DTH) response to tubular antigen is a T cell-dependent Intensity of direct immunofluorescence reported as mean 5EM. Graded histologic sections reported as the mean SEM. ci Creatinines reported as mean mg %.
Reported as cells/cubic mm. * P c 0.001 compared to RTA/CFA group on day 33. Cyclophosphamide (CTX; 15 mg/kg/day) was administered from days 12 to 33. All control groups were injected with 0.5 cc H20/day during the treatment time in which the animals in the same experiment received their CTX.
Data points from 4 to 6 rats per measurement were calculated as the mean increment inches x l0 5EM, 33 days alter immunization, 24
hours after challenge with antigen. * P c 0.001 compared to unimmunized controls.
and antigen-specific measure of nephritogenic potential [2] . In Table 3 , DTH responses were measured in rats followed to day 33. The results indicate that rats treated from days 12 to 33 with 15 mg/kg/day of cyclophosphamide developed a non-specific and severe impairment of DTR, as the response to both SRTA and PPD were reduced. Effects of daily cyclophosphamide administration beginning late (21 days) after immunization to produce disease. In this last group of experiments, rats were treated with 15 mg/kg/day of cyclophosphamide from days 21 to 42 (Table 4) , and compared to non-treated controls immunized with RTA and CFA and sacrificed at days 21 and 42. The time-control group sacrificed on day 21 revealed significant interstitial damage. Rats followed to day 42 demonstrated a progression of histologic disease which was not observed in the group receiving cyclophosphamide (P c 0.01). All rats immunized with RTA/CFA showed significant kidney-bound aTBM-Ab, and the serum aTBM-Ab titer of the group receiving cyclophosphamide did not increase beyond that observed in rats sacrificed on day 21 (Fig. 1C) . A significant effect of cyclophosphamide was again demonstrated on the WBC count (Tahle 4).
Discussion
The findings in the present study indicate that cyclophosphamide at 15 mg/kg/day is well tolerated in the rat, and can effectively and completely prevent the development of primary interstitial renal lesions when given at the time of immunization.
This observation is consistent with previous findings that one large dose of cyclophosphamide (200 mg/kg) within 72 hours of immunization can inhibit the development of interstitial disease in guinea pigs [17] . If cyclophosphamide is used early after disease is present, we also noted that it can retard the progression of renal damage. Even if cyclophosphamide is administered late in the disease there still is a reduction in progression, although considerable interstitial injury remains. The use of lower doses of cyclophosphamide (2 mg/kg/day), however, resulted in more severe lesions at 21 days (Table 1) . Such a seemingly parodoxical finding can be explained by previous observations that low-dose cyclophosphamide can eliminate either non-specific suppressor cells [2] or autologous cellmediated tolerance (C. Kelly; manuscript in preparation) which results in more severe cellular interstitial injury. In some experimental systems low-dose cyclophosphamide also seems to preferentially inhibit suppressor T cells when compared to the helper cell subpopulation [18, 19] .
The mechanism of the protective effect at a dose of 15 mg/kg/day appears to be principally directed towards the cellular immune response; that is, when cyclophosphamide was begun at the time of immunization, neither a B cell response nor a mixed cellular lesion ever evolved. When cyclophosphamide was started 12 days after immunization, however, significant amounts of aTBM-Ab were present, but the cell-mediated effector response, reflected in a delayed-type hypersensitivity reaction, was non-specifically impaired. This lack of cyclophosphamide effect on previously established antibody responses has also been observed in other experimental systems [20] . It is also unlikely that the reduction in cell-mediated immunity was due to the induction of a non-specific suppressor cell mechanism, as such suppressor cells usually are cyclophosphamidesensitive [2] .
The current observations from our work are also supported by previous findings where cyclophosphamide was used to treat interstitial nephritis associated with autoimmune glomerulonephritis in mice [6] . The daily dose of 15 mg/kg/day was chosen for the present studies because it has been previously shown that mice can tolerate such a treatment regimen without noticeable side effects [4] [5] [6] . The BN rat also can tolerate this dose schedule, and no animals were lost in any of the treatment groups during the course of our study. It appears, in fact, that noticeable increases in mortality from the drug are only manifest after doses of 20 mg/kg/day [21] . A direct dose comparison a All control groups were injected with 0.5 cc H20/day during the treatment time in which the animals in the same experiment received their cyclophosphamide (CTX).
b Intensity of direct immunofluorescence reported as mean SEM. Graded histologic sections reported as the mean SEM. d Creatinines reported as mean mg %.
Reported as cells/cubic mm.
* P < 0.01 compared to RTAJCFA group on day 42.
with man, however, is not really possible, as all metabolites of cyclophosphamide have not been formally measured on a kinetic basis in rats. Overall alkylating activity, which bears a relationship to levels of metabolites, has nevertheless been determined in both species [22] . While peak alkylating activity in man is 50-75% of that in the rat, the elimination constant in man is only 66% of that in the rat. Furthermore, although the kinetics of metabolite blood levels are important for the cytostatic effect of cyclophosphamide [23] , other unknown bone marrow factors in rats may contribute to the tolerance of the drug during long-term usage, as most humans do not tolerate 15 mg/kg/day of cyclophosphamide. In summary, our data suggest that cyclophosphamide can be used to modify the expression of interstitial nephritis, Our findings also suggest that the earlier it is used, the better the protective effect, and that higher doses are required as opposed to lower doses which may actually potentiate the expression of disease. Whether this protection extends beyond the time when cyclophosphamide is discontinued remains to be determined.
